Results 171 to 180 of about 29,245 (221)
Some of the next articles are maybe not open access.
Catalytic inhibitors of DNA topoisomerase II
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1998Catalytic inhibitors of mammalian DNA topoisomerase II have been found recently in natural and synthetic compounds. These compounds target the enzyme within the cell and inhibit various genetic processes involving the enzyme, such as DNA replication and chromosome dynamics, and thus proved to be good probes for the functional analyses of the enzyme in ...
T, Andoh, R, Ishida
openaire +2 more sources
Drug resistance to topoisomerase II inhibitors
Biochimie, 1998We describe in this review the mechanisms of resistance to topoisomerase II inhibitors that have been identified in cell lines rendered resistant to drugs. They concern especially both quantitative and qualitative alterations of topoisomerase II, leading to drug insensitivity of the cells.
J, Robert, A K, Larsen
openaire +2 more sources
Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry, 2012Type II topoisomerases (TOPO2) are ubiquitously expressed enzymes that overcome topological problems in genomic DNA, which can result from DNA replication, transcription and repair. The class of compounds targeting TOPO2 includes some of the most active chemotherapy agents currently available for the treatment of patients with different cancer types ...
Pilati P +2 more
openaire +3 more sources
Cytotoxic signalling by inhibitors of DNA topoisomerase II
Biochemical Society Transactions, 2001DNA topoisomerase (topo) II inhibitors either stabilize DNA–topo II complexes by blocking DNA religation (e.g. etoposide) or block the enzyme's catalytic activity (e.g. dexrazoxane). The former class of drugs causes direct DNA damage through topo II, while the latter class does not, but both classes cause apoptosis.
W T, Beck, Y Y, Mo, U G, Bhat
openaire +2 more sources
Toxicity of the topoisomerase II inhibitors
Expert Opinion on Drug Safety, 2005The topoisomerase I inhibitors represent a class of antineoplastic agents with a wide spectrum of activity against malignancies. Currently available topo-isomerase I inhibitors are derivatives of the parent compound, camptothecin. Irinotecan is most active against gastrointestinal (GI) tumours, and has predominantly GI and haematological toxicities ...
openaire +3 more sources
The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure
Parasitology Research, 2004Topoisomerases from trypanosomatids play key functions in the replication and organization of kinetoplast DNA (kDNA). Hence, they are considered as potential targets for anti-parasite drugs. In this paper, the effect of topoisomerase II inhibitors, such as nalidixic acid, novobiocin and etoposide, on the ultrastructure of trypanosomatids that present ...
Danielle P, Cavalcanti +4 more
openaire +2 more sources
Acridine derivatives as inhibitors/poisons of topoisomerase II
Journal of Applied Toxicology, 2021AbstractThe potential of acridines (amsacrine) as a topoisomerase II inhibitor or poison was first discovered in 1984, and since then, a considerable number of acridine derivatives have been tested as topoisomerase inhibitors/poisons, containing different substituents on the acridine chromophore.
openaire +2 more sources
Bimolane: in vitro inhibitor of human topoisomerase II
Cancer Letters, 1997Bimolane is a member of the bis(2,6-dioxopiperazine) class of drugs and has been widely used in China as an anti-neoplastic agent and for the treatment of psoriasis. Recent case reports indicate that bimolane is leukemogenic and is thought to exert its effects through the inhibition of topoisomerase II. However, there are no data showing the inhibition
C E, Frantz +4 more
openaire +2 more sources
Induction of endoreduplication by topoisomerase II catalytic inhibitors
Mutagenesis, 2003The striking phenomenon of endoreduplication has long attracted attention from cytogeneticists and researchers into cell cycle enzymology and dynamics alike. Because of the variety of agents able to induce endoreduplication and the various cell types where it has been described, until now no clear or unique mechanism of induction of this phenomenon ...
Felipe, Cortés, Nuria, Pastor
openaire +2 more sources
Catalytic topoisomerase II inhibitors in cancer therapy
Pharmacology & Therapeutics, 2003The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents. All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle. Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while ...
Annette K, Larsen +2 more
openaire +2 more sources